Drug intelligence / Profile preview

thirst granule (045963)

Development stage: Preclinical
Lead developer: First Affiliated Hospital of Anhui University of Chinese Medicine
Administration: Oral

Overview

Thirst granule (渴颗粒) is a Traditional Chinese Medicine (TCM) herbal preparation developed by The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine. It is primarily investigated for the treatment of prediabetes and type 2 diabetes mellitus. In the context of TCM, the formula is likely designed to address "Xiao Ke" (wasting and thirsting disorder), a traditional categorization of diabetes-like symptoms, by regulating glucose metabolism and potentially improving insulin sensitivity. Clinical research, such as the trial registered under ChiCTR2400090766, focuses on evaluating the safety and effectiveness of thirst granule intervention in preventing the progression of prediabetes to overt diabetes.

Other names: Keke Granule渴颗粒

Beyond the preview

Go deeper on thirst granule (045963).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on thirst granule (045963).

Explore the full profile